Pirfenidone: A Novel Pharmacological Agent That Inhibits Leiomyoma Cell Proliferation and Collagen Production
The DOI matches its Crossref record.
Abstract
There are currently no effective, long-term drug therapies for the treatment of leiomyomas. Pirfenidone (Marnac, Inc.) is an antifibrotic agent that is being tested for use in patients with pulmonary fibrosis. Because leiomyomas are characterized also by increased cell proliferation and tissue fibrosis, we examined the effects of pirfenidone on cell proliferation and collagen expression in cultured myometrial and leiomyoma smooth muscle cells. Effects of pirfenidone on proliferation of myometrial and leiomyoma cells were measured using tritiated thymidine incorporation assays and changes in actual cell numbers. Possible cytotoxic effects were examined using lactate dehydrogenase assays and trypan blue exclusion. Effects on collagen type I and type III production were assessed by Northern blotting. Doses of pirfenidone tested were: 0, 0.01, 0.1, 0.3, and 1.0 mg/mL. Serum-stimulated increases in DNA synthesis and cell proliferation by myometrial and leiomyoma cells were significantly inhibited in a dose-dependent manner by pirfenidone. Densitometric analysis of Northern blots showed significantly decreased expression of collagen type I and type III messenger RNAs in both leiomyoma and myometrial cells. Lactate dehydrogenase assays and trypan blue exclusion measurements showed no cytotoxic effect of pirfenidone at concentrations that inhibited cell proliferation and collagen production. Pirfenidone is an effective inhibitor of myometrial and leiomyoma cell proliferation in vitro and reduces the messenger RNA levels of collagen types I and III in a dose-dependent manner. This compound may prove to be an effective nonsteroidal therapy for treatment of uterine leiomyomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Richeldi, L., Collard, H. R., & Jones, M. G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30866-8 · Cited by 2,020
THE CARDIAC FIBROBLAST: Therapeutic Target in Myocardial Remodeling and Failure
Brown, R. D., Ambler, S. K., Mitchell, M. D., & Long, C. S. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095802 · Cited by 647
Antifibrotic activities of pirfenidone in animal models
Schaefer, C. J., Ruhrmund, D. W., Pan, L., Seiwert, S. D., & Kossen, K. (2011) · European Respiratory Review · doi:10.1183/09059180.00001111 · Cited by 454
Conte, E., Gili, E., Fagone, E., Fruciano, M., Iemmolo, M., & Vancheri, C. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.02.014 · Cited by 368
Extracellular matrix in uterine leiomyoma pathogenesis: a potential target for future therapeutics
Islam, M. S., Ciavattini, A., Petraglia, F., Castellucci, M., & Ciarmela, P. (2018) · Human Reproduction Update · doi:10.1093/humupd/dmx032 · Cited by 321
Pirfenidone inhibits the expression of HSP47 in TGF-β1-stimulated human lung fibroblasts
Nakayama, S., Mukae, H., Sakamoto, N., Kakugawa, T., Yoshioka, S., Soda, H., Oku, H., Urata, Y., Kondo, T., Kubota, H., et al. (2008) · Life Sciences · doi:10.1016/j.lfs.2007.11.003 · Cited by 165
Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production
Di Sario, A., Bendia, E., Svegliati Baroni, G., Ridolfi, F., Casini, A., Ceni, E., Saccomanno, S., Marzioni, M., Trozzi, L., Sterpetti, P., et al. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00245-3 · Cited by 138
Sun, Y., Zhang, Y., & Chi, P. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9423 · Cited by 50
Zheng, Y., Schupp, J., Adams, T., Clair, G., Justet, A., Ahangari, F., Yan, X., Hansen, P., Carlon, M., Cortesi, E., et al. (2023) · doi:10.21203/rs.3.rs-3676579/v1 · Cited by 34
Metadata
- Authors
- Lee, B.-S.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1998-01-01
- Volume
- 83
- Issue
- 1
- Pages
- 219-223
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2171180036
- Cited by
- 107
- References
- 0
- FWCI
- 4.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.